Cargando…
NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. W...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159985/ https://www.ncbi.nlm.nih.gov/pubmed/34045513 http://dx.doi.org/10.1038/s41598-021-90361-w |
_version_ | 1783700188346449920 |
---|---|
author | Marchetti, Claudia D’Indinosante, Marco Bottoni, Carolina Di Ilio, Chiara Di Berardino, Stefano Costantini, Barbara Minucci, Angelo Vertechy, Laura Scambia, Giovanni Fagotti, Anna |
author_facet | Marchetti, Claudia D’Indinosante, Marco Bottoni, Carolina Di Ilio, Chiara Di Berardino, Stefano Costantini, Barbara Minucci, Angelo Vertechy, Laura Scambia, Giovanni Fagotti, Anna |
author_sort | Marchetti, Claudia |
collection | PubMed |
description | Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. We consecutively enrolled a series of 397 newly diagnosed high-grade serous-advanced OC-patients. All patients were tested for BRCA-mutational-status and blood-parameters have been collected 48 h before staging-surgery. A significant correlation of NLR with disease distribution (p < 0.005) was found and patients with NLR < 4 underwent primary-debulking-surgery more frequently (p-value 0.001), with a lower surgical-complexity-score (p-value 0.002). Regarding survival-data, patients with NLR < 4 had a significant 7-month increase in mPFS (26 vs 19 months, p = 0.009); focusing on the BRCA-status, among both BRCA-mutated and BRCA-wild type patients, those with lower NLR had a significantly prolonged mPFS compared to patients with NLR > 4 (BRCA-mutated: 35 vs 23 months, p = 0.03; BRCA-wt: 19 vs 16 months, p = 0.05). At multivariate-analysis, independent factors of prolonged PFS were BRCA mutational status, having received complete cytoreduction and NLR < 4. Also, the strongest predictors of longer OS were BRCA-mutational status, having received complete cytoreductive surgery, NLR < 4 and age. NLR is confirmed to be a prognostic marker in OC-patients and it seems unrelated with BRCA-mutational status. |
format | Online Article Text |
id | pubmed-8159985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81599852021-05-28 NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer Marchetti, Claudia D’Indinosante, Marco Bottoni, Carolina Di Ilio, Chiara Di Berardino, Stefano Costantini, Barbara Minucci, Angelo Vertechy, Laura Scambia, Giovanni Fagotti, Anna Sci Rep Article Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. We consecutively enrolled a series of 397 newly diagnosed high-grade serous-advanced OC-patients. All patients were tested for BRCA-mutational-status and blood-parameters have been collected 48 h before staging-surgery. A significant correlation of NLR with disease distribution (p < 0.005) was found and patients with NLR < 4 underwent primary-debulking-surgery more frequently (p-value 0.001), with a lower surgical-complexity-score (p-value 0.002). Regarding survival-data, patients with NLR < 4 had a significant 7-month increase in mPFS (26 vs 19 months, p = 0.009); focusing on the BRCA-status, among both BRCA-mutated and BRCA-wild type patients, those with lower NLR had a significantly prolonged mPFS compared to patients with NLR > 4 (BRCA-mutated: 35 vs 23 months, p = 0.03; BRCA-wt: 19 vs 16 months, p = 0.05). At multivariate-analysis, independent factors of prolonged PFS were BRCA mutational status, having received complete cytoreduction and NLR < 4. Also, the strongest predictors of longer OS were BRCA-mutational status, having received complete cytoreductive surgery, NLR < 4 and age. NLR is confirmed to be a prognostic marker in OC-patients and it seems unrelated with BRCA-mutational status. Nature Publishing Group UK 2021-05-27 /pmc/articles/PMC8159985/ /pubmed/34045513 http://dx.doi.org/10.1038/s41598-021-90361-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Marchetti, Claudia D’Indinosante, Marco Bottoni, Carolina Di Ilio, Chiara Di Berardino, Stefano Costantini, Barbara Minucci, Angelo Vertechy, Laura Scambia, Giovanni Fagotti, Anna NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer |
title | NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer |
title_full | NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer |
title_fullStr | NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer |
title_full_unstemmed | NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer |
title_short | NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer |
title_sort | nlr and brca mutational status in patients with high grade serous advanced ovarian cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159985/ https://www.ncbi.nlm.nih.gov/pubmed/34045513 http://dx.doi.org/10.1038/s41598-021-90361-w |
work_keys_str_mv | AT marchetticlaudia nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT dindinosantemarco nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT bottonicarolina nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT diiliochiara nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT diberardinostefano nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT costantinibarbara nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT minucciangelo nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT vertechylaura nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT scambiagiovanni nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer AT fagottianna nlrandbrcamutationalstatusinpatientswithhighgradeserousadvancedovariancancer |